Medicines Evaluation Board

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Utrecht University荷兰7
2. Erasmus MC荷兰6
3. European Medicines Agency荷兰5
4. University Medical Center Groningen荷兰4
5. University of Iceland冰岛3
6. Netherlands Pharmacovigilance Centre Lareb荷兰3
7. Medicines and Healthcare products Regulatory Agency英国2
8. University of Groningen荷兰2

按月发文

逐年被引

最新文献

1. 1
   Risk Minimisation Measures of Advanced Therapy Medicinal Products Authorised in the EU Between 2009 and 2023: A Cross-Sectional StudyDrug Safety20253
2. 2
   Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and RecommendationsPharmacoepidemiology and Drug Safety20244
3. 3
   Do efficacy results obtained from randomized controlled trials translate to effectiveness data from observational studies for relapsing–remitting multiple sclerosis?Pharmacoepidemiology and Drug Safety20241
4. 4
   The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety GloballyDrug Safety20249
5. 5
   An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilanceDrug Safety202315
6. 6
   Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021Drug Safety20238
7. 7
   What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey StudyDrug Safety20232
8. 8
   Analysis of Reports on Adverse Drug Reactions Related to Herbal Medicinal Products and Herbal Supplements in the Netherlands Received by the National Pharmacovigilance Centre LarebDrug Safety202224
9. 9
   Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle – a focus on benefits and risksExpert Opinion on Drug Safety20217
10. 10
    Signals from the Dutch national spontaneous reporting system: Characteristics and regulatory actionsPharmacoepidemiology and Drug Safety202112

高被引文献

1. 1
   EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health ProtectionDrug Safety2018136
2. 2
   Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?Drug Safety201674
3. 3
   Characteristics of drugs safety signals that predict safety related product information updatePharmacoepidemiology and Drug Safety201833
4. 4
   Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint ActionDrug Safety201832
5. 5
   Registries supporting new drug applicationsPharmacoepidemiology and Drug Safety201731
6. 6
   Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase StudyDrug Safety201928
7. 7
   Analysis of Reports on Adverse Drug Reactions Related to Herbal Medicinal Products and Herbal Supplements in the Netherlands Received by the National Pharmacovigilance Centre LarebDrug Safety202224
8. 8
   Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in EuropeDrug Safety202016
9. 9
   An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilanceDrug Safety202315
10. 10
    Signals from the Dutch national spontaneous reporting system: Characteristics and regulatory actionsPharmacoepidemiology and Drug Safety202112

主要发表期刊

研究主题